Atezolizumab plus nab-paclitaxel for unresectable, locally advanced or metastatic breast cancer: real-world results from a single academic center in Austria.

BMC Cancer · 2022 · PMC9609239 · PMID 36289467

Europe PMC DOI

hedged sentence

0.0890

closest p · 1.8× alpha

0.0890

boldest claim

The sentences

marginally significantp = 0.089so close (0.05 < p ≤ 0.1)

PFS showed a marginally significant negative association with the treatment line, with a shorter PFS duration in later treatment lines (r s ( n = 16) = -0.36; p = 0.089, Spearman ́s rank correlation).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.